Insider · CIK 0001733272
Frank Yocca
Files at BTAIQ (BioXcel Therapeutics, Inc.). First filing Dec 17, 2024, latest May 22, 2026.
Frank Yocca files SEC Form 4 as officer at BTAIQ (BioXcel Therapeutics, Inc.). Since Dec 17, 2024, Frank Yocca has reported 0 open-market buys worth $0 and 2 open-market sells worth $7,579, the latest filed on May 22, 2026.
A track record needs three past buys with six months of prices behind them; Frank Yocca has 0, so none is measured yet.
The newest scored trade: sold $7,427 of BTAIQ on May 20, 2026, filed May 22, 2026, scored 0 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $7,427.
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | BioXcel Therapeutics, Inc. | $7,427 6,845 shares | -21% | - | |
| 0Weak | BioXcel Therapeutics, Inc. | $152 430 shares | -1% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 16, 2024 | BTAIQ BioXcel Therapeutics, Inc. | 430 0.00% of outstanding | $152 | Dec 16, 2024 | $4,191 |
Transactions
Every row this insider has filed, 38 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +35 | - | - | 26,210 | Jun 17, 2026 |
| Jun 15, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -35 | $0.00 | $0 | 212 | Jun 17, 2026 |
| May 4, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +17,500 | - | - | 33,020 | May 22, 2026 |
| May 20, 2026 | BTAIQ BioXcel Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -6,845 | $1.09 | $7,427 | 26,175 | May 22, 2026 |
| May 4, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative10b5-1 | -17,500 | $0.00 | $0 | 52,500 | May 22, 2026 |
| May 1, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +9,000 | - | - | 15,520 | May 7, 2026 |
| May 1, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -9,000 | $0.00 | $0 | 0 | May 7, 2026 |
| Mar 14, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +33 | - | - | 6,485 | Mar 16, 2026 |
| Mar 15, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +35 | - | - | 6,520 | Mar 16, 2026 |
| Mar 14, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -33 | $0.00 | $0 | 97 | Mar 16, 2026 |
| Mar 15, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -35 | $0.00 | $0 | 247 | Mar 16, 2026 |
| Jan 1, 2026 | BTAIQ BioXcel Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +70,000 | $0.00 | $0 | 70,282 | Jan 5, 2026 |
| Dec 14, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +33 | - | - | 6,417 | Dec 15, 2025 |
| Dec 15, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +35 | - | - | 6,452 | Dec 15, 2025 |
| Dec 14, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -33 | $0.00 | $0 | 130 | Dec 15, 2025 |
| Dec 15, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -35 | $0.00 | $0 | 282 | Dec 15, 2025 |
| Sep 14, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +33 | - | - | 6,349 | Sep 16, 2025 |
| Sep 15, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +35 | - | - | 6,384 | Sep 16, 2025 |
| Sep 14, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -33 | $0.00 | $0 | 163 | Sep 16, 2025 |
| Sep 15, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -35 | $0.00 | $0 | 317 | Sep 16, 2025 |
| Aug 1, 2025 | BTAIQ BioXcel Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +9,000 | $0.00 | $0 | 9,000 | Aug 5, 2025 |
| Jul 22, 2025 | BTAIQ BioXcel Therapeutics, Inc. | AGrant or award Common Stock | +4,375 | - | - | 6,316 | Jul 22, 2025 |
| Jun 14, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +33 | - | - | 1,906 | Jun 16, 2025 |
| Jun 15, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +35 | - | - | 1,941 | Jun 16, 2025 |
| Jun 14, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -33 | $0.00 | $0 | 196 | Jun 16, 2025 |
| Jun 15, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -35 | $0.00 | $0 | 352 | Jun 16, 2025 |
| Jul 22, 2024 | BTAIQ BioXcel Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +1,875 | $0.00 | $0 | 1,875 | Apr 1, 2025 |
| Mar 14, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +31 | - | - | 1,839 | Mar 17, 2025 |
| Mar 15, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +34 | - | - | 1,873 | Mar 17, 2025 |
| Mar 14, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -31 | $0.00 | $0 | 229 | Mar 17, 2025 |
| Mar 15, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -34 | $0.00 | $0 | 387 | Mar 17, 2025 |
| Jan 7, 2025 | BTAIQ BioXcel Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +270,000 | $0.00 | $0 | 270,000 | Jan 10, 2025 |
| Dec 14, 2024 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +521 | - | - | 28,799 | Dec 17, 2024 |
| Dec 15, 2024 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +562 | - | - | 29,361 | Dec 17, 2024 |
| Dec 16, 2024 | BTAIQ BioXcel Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -205 | $0.36 | $73 | 29,156 | Dec 17, 2024 |
| Dec 16, 2024 | BTAIQ BioXcel Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -225 | $0.35 | $79 | 28,931 | Dec 17, 2024 |
| Dec 14, 2024 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative10b5-1 | -521 | $0.00 | $0 | 2,606 | Dec 17, 2024 |
| Dec 15, 2024 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative10b5-1 | -562 | $0.00 | $0 | 5,064 | Dec 17, 2024 |
Questions about Frank Yocca
Answered from the filings on this page, as of the latest one.
Is Frank Yocca buying or selling?
In the last 12 months Frank Yocca reported 0 open-market buys worth $0 and 1 open-market sell worth $7,427 on SEC Form 4; the latest was sold $7,427 of BTAIQ on May 20, 2026. Grants, option exercises and tax withholding are not counted.
How did Frank Yocca's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Frank Yocca has 0.
Where does Frank Yocca file Form 4?
Frank Yocca has filed Form 4 at BTAIQ (BioXcel Therapeutics, Inc.) as Chief Scientific Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.